Literature DB >> 3858979

Localization of omeprazole and metabolites in the mouse.

H F Helander, C H Ramsay, C G Regårdh.   

Abstract

Omeprazole is a substituted benzimidazole which blocks gastric acid secretion by inhibiting H+K+ATPase. Radioactive omeprazole was given intravenously or orally to mice, and the distribution of the drug was investigated at various intervals by scintillation counting and by autoradiography. The half-life for radioactivity in the stomach was 14 hours versus 30-36 hours in the liver, kidneys and blood. At 16 hours after the drug was given, the radioactivity in the stomach was ten times higher than that in the liver and kidneys, and 100 times that in the blood. Whole-body autoradiography showed sustained high levels of radioactivity only in the gastric mucosa. Light microscopic autoradiographic investigations of the gastric mucosa from mice killed 1 or 16 hours after the drug was given revealed radioactivity in the parietal cells. By electron microscopy of gastric mucosa from the mouse killed 16 hours after omeprazole injection the isotope label was found mainly over the secretory surface and the tubulo-vesicles. At these locations H+K+ATPase has previously been demonstrated, and it is suggested that omeprazole--or its metabolites--binds to this enzyme.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3858979     DOI: 10.3109/00365528509095822

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  16 in total

1.  Antisecretory therapy and genotoxicity.

Authors:  S Holt; R E Powers; C W Howden
Journal:  Dig Dis Sci       Date:  1991-05       Impact factor: 3.199

Review 2.  Gastric H,K-ATPase as a drug target.

Authors:  Jai Moo Shin; George Sachs
Journal:  Dig Dis Sci       Date:  2006-04-28       Impact factor: 3.199

3.  Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.

Authors:  R K Brazzell; P R Mayer; R Dobbs; P J McNamara; R L Teng; J T Slattery
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

5.  Effects of NC-1300-B, a new benzimidazole derivative, on hog gastric H+, K+-ATPase, gastric acid secretion and HCl.ethanol-induced gastric lesions in rats.

Authors:  S Okabe; Y Akimoto; S Yamasaki; H Nagai
Journal:  Dig Dis Sci       Date:  1988-11       Impact factor: 3.199

6.  Pharmacological inhibition of soluble epoxide hydrolase or genetic deletion reduces diclofenac-induced gastric ulcers.

Authors:  Sumanta Kumar Goswami; Amelia Ann Rand; Debin Wan; Jun Yang; Bora Inceoglu; Melany Thomas; Christophe Morisseau; Guang-Yu Yang; Bruce D Hammock
Journal:  Life Sci       Date:  2017-05-15       Impact factor: 5.037

7.  Effect of omeprazole on gastric first-pass metabolism of ethanol.

Authors:  R Roine; R Hernández-Muñoz; E Baraona; R Greenstein; C S Lieber
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

Review 8.  Omeprazole. Overview and opinion.

Authors:  S Holt; C W Howden
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

9.  Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.

Authors:  K Nagata; H Satoh; T Iwahi; T Shimoyama; T Tamura
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 10.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.